ARVN logo

Arvinas (ARVN) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 September 2018

Indexes:

Not included

Description:

Arvinas, Inc. is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases by discovering, developing, and commercializing treatment methods that target disease-causing proteins. Arvinas utilizes its patented PROTAC Discovery Engine platform. The company was founded in 2015 and is based in New Haven, Connecticut. The therapeutic focus of the issuer includes oncological diseases, neurological disorders, and other serious illnesses. Arvinas, Inc. has two leading product candidates: ARV-110 - for the treatment of men with metastatic castration-resistant prostate cancer ARV-471 - for the treatment of patients with locally advanced or metastatic ER-positive / HER2-negative breast cancer.

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Oct 30, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

12 Dec '24 Guggenheim
Buy
11 Dec '24 HC Wainwright & Co.
Buy
20 Nov '24 BMO Capital
Outperform
18 Nov '24 Stephens & Co.
Overweight
31 Oct '24 Oppenheimer
Outperform
31 Oct '24 HC Wainwright & Co.
Buy
09 Sept '24 Cantor Fitzgerald
Overweight
01 Aug '24 HC Wainwright & Co.
Buy
31 July '24 Wedbush
Outperform
31 July '24 Oppenheimer
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
ARVN
accesswire.com03 January 2025

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
ARVN
accesswire.com31 December 2024

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
ARVN
accesswire.com30 December 2024

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
ARVN
accesswire.com29 December 2024

NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
ARVN
prnewswire.com27 December 2024

NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
ARVN
accesswire.com26 December 2024

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
ARVN
accesswire.com24 December 2024

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
ARVN
accesswire.com17 December 2024

NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
ARVN
accesswire.com16 December 2024

NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
ARVN
accesswire.com15 December 2024

NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

FAQ

  • What is the primary business of Arvinas?
  • What is the ticker symbol for Arvinas?
  • Does Arvinas pay dividends?
  • What sector is Arvinas in?
  • What industry is Arvinas in?
  • What country is Arvinas based in?
  • When did Arvinas go public?
  • Is Arvinas in the S&P 500?
  • Is Arvinas in the NASDAQ 100?
  • Is Arvinas in the Dow Jones?
  • When was Arvinas's last earnings report?
  • When does Arvinas report earnings?
  • Should I buy Arvinas stock now?

What is the primary business of Arvinas?

Arvinas, Inc. is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases by discovering, developing, and commercializing treatment methods that target disease-causing proteins. Arvinas utilizes its patented PROTAC Discovery Engine platform. The company was founded in 2015 and is based in New Haven, Connecticut. The therapeutic focus of the issuer includes oncological diseases, neurological disorders, and other serious illnesses. Arvinas, Inc. has two leading product candidates: ARV-110 - for the treatment of men with metastatic castration-resistant prostate cancer ARV-471 - for the treatment of patients with locally advanced or metastatic ER-positive / HER2-negative breast cancer.

What is the ticker symbol for Arvinas?

The ticker symbol for Arvinas is NASDAQ:ARVN

Does Arvinas pay dividends?

No, Arvinas does not pay dividends

What sector is Arvinas in?

Arvinas is in the Healthcare sector

What industry is Arvinas in?

Arvinas is in the Biotechnology industry

What country is Arvinas based in?

Arvinas is headquartered in United States

When did Arvinas go public?

Arvinas's initial public offering (IPO) was on 27 September 2018

Is Arvinas in the S&P 500?

No, Arvinas is not included in the S&P 500 index

Is Arvinas in the NASDAQ 100?

No, Arvinas is not included in the NASDAQ 100 index

Is Arvinas in the Dow Jones?

No, Arvinas is not included in the Dow Jones index

When was Arvinas's last earnings report?

Arvinas's most recent earnings report was on 30 October 2024

When does Arvinas report earnings?

The next expected earnings date for Arvinas is 27 February 2025

Should I buy Arvinas stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions